Lymph node cancer

Summary

Lymph node cancer (MONDO:0001082) is a cancer (an umbrella term covering 5 Mondo subtypes) and 18 clinical trials. Top therapeutic interventions include ferumoxytol and nivolumab. A subtype of lymphatic system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 5 Mondo subtypes
• Clinical trials: 18

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lymph node cancer
Mondo ID	MONDO:0001082
DOID	DOID:10619
NCIT	C35812
SNOMED CT	127232002
UMLS	C0948627
MedGen	182690
GARD	0022877
Anatomy (UBERON)	UBERON:0000029
Is cancer (heuristic)	yes

Also known as: cancer of lymph node · lymph node cancer · lymph node neoplasm · malignant lymph node neoplasm · malignant neoplasm of lymph node

Disease family

This is a subtype of lymphatic system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › lymphatic system cancer › lymph node cancer

Related subtypes (3): lymphosarcoma, spleen cancer, reticulum cell sarcoma

Subtypes (5): lymph node adenoid cystic carcinoma, intrapelvic lymph node leukemic reticuloendotheliosis, intra-abdominal lymph node mast cell malignancy, metastatic malignant neoplasm in the lymph nodes, lymph node carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 18.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	17
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03618641	PHASE2	COMPLETED	CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease
NCT06527027	Not specified	RECRUITING	LN-RADS, RECIST 1.1 and Node-RADS Classification in the Assessment of Lymph Nodes
NCT06725628	Not specified	NOT_YET_RECRUITING	Multiomics Study of Biological Behavior of Lymph Node Metastasis in Papillary Thyroid Carcinoma
NCT07112599	Not specified	RECRUITING	Study of Predicting Lymph Node Metastasis of High-risk Prostate Cancer by Artificial Intelligence Multi-omics Analysis
NCT07538960	Not specified	NOT_YET_RECRUITING	Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.
NCT01360411	Not specified	COMPLETED	Tissue Characterisation by Endoscopic GI-elastography
NCT01815333	Not specified	COMPLETED	Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging
NCT02156414	Not specified	COMPLETED	Lymph Node Involvement Using Extended Pelvic Lymphadenectomy in Clinically Localized Prostate Cancer
NCT02298010	Not specified	COMPLETED	Lymph Node Metastasis in Extended Lymphadenectomy for Gastric Cancer From a CLASSIC Trial
NCT02408835	Not specified	UNKNOWN	Negative Pressure Wound Therapy in Groin Dissection
NCT02459041	Not specified	COMPLETED	Clinical Impact of EUS Elastography Mean Strain Histograms (SH) and Contrast Peak-enhancement in Focal Pancreatic Masses and Lymph Nodes
NCT02508909	Not specified	COMPLETED	Videoscopic Ilioinguinal Lymphadenectomy for Melanoma
NCT02555592	Not specified	UNKNOWN	Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level
NCT02570399	Not specified	UNKNOWN	High Dose SBRT for Abdominal-Pelvic Lymph Nodal Lesions in Oligometastatic Patients
NCT04553744	Not specified	WITHDRAWN	Identification of Surgical Management of Lymph Node Basins and Surgical Practice Patterns Among Sarcoma Surgeons
NCT05040685	Not specified	COMPLETED	Axillary Reverse Mapping in Breast Cancer
NCT05287880	Not specified	UNKNOWN	Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC
NCT05873621	Not specified	UNKNOWN	Indocyanine Green-guided Lymphadenectomy in Laparoscopic Total Mesorectal Excision for Low Rectal Cancer After Neoadjuvant Chemoradiotherapy

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FERUMOXYTOL	4	1
NIVOLUMAB	4	1